Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Chronic Pelvic Pain Syndromes: Clinical, Urodynamic, And Urothelial Observations
UroToday.com - Patients with pain can present with various symptom complexes that include interstitial cystitis, vulvodynia, irritable bowel syndrome, myofascial pain or various causes of dyspareunia but when carefully evaluated, the majority have very similar findings. No matter what their primary complaint might be over 70% of patients will have hypertonic pelvic floor dysfunction and/or pain as well as a component of at least one visceral pain syndrome such as interstitial cystitis (the most common), chronic pelvic pain or irritable bowel syndrome.

Provectus Reports Encouraging Clinical Data At ASCO On Treatment Of Metastatic Melanoma With PV-10
Provectus Pharmaceuticals, Inc. (OTC Bulletin Board: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has announced interim data from the first 40 subjects in its Phase 2 clinical trial for the treatment of metastatic melanoma. PV-10 treatment was well tolerated and caused selective tumor destruction in the majority of subjects. Additional data on untreated tumors corroborated observations of a possible bystander effect seen during earlier Phase 1 testing. These data were presented today at the American Society of Clinical Oncology 2009 Annual Meeting, Abstract #9060, entitled "Chemoablation of melanoma with intralesional rose bengal (PV-10)," in the General Poster Session.
News of the day
USC Researchers Identify DNA Mutation That Occurs At Beginning Point Of T-Cell Lymphoma
Researchers at the Keck School of Medicine of the University of Southern California (USC) have identified a key mechanism that causes chromosomes within blood cells to break - an occurrence that marks the first step in the development of human lymphoma.
Sexual Health

New Research Claims Cholesterol Drug Could Reduce Risk Of Amputations In People With Diabetes

People with diabetes who were prescribed the cholesterol-lowering drug fenofibrate reduced their risk of minor amputations by 36 per cent, according to new research. Researchers in Australia, Finland and New Zealand looked at almost 10,000 people aged between 50 and 75 with Type 2 diabetes. About half of them were given fenofibrate while the other half were given placebos. New discovery The study, first published in 2005, aimed to see if fenofibrate prevented heart disease, which it did not. But in this new analysis, experts found patients on fenofibrate had a 36 per cent lower risk of a first amputation than those on the placebo. The risk of minor amputations in people without large vessel arterial disease was nearly 50 per cent lower in the group taking fenofibrates, but the risk of a major amputation was not substantially different between the two groups. Taller people were also more likely to have amputations. Fenofibrates can cause side effects including abdominal pain, nausea, pancreas and lung problems. Leading research forward "This large trial suggests that the drug fenofibrate could play a role in the reduction of below-the-ankle amputations in people with Type 2 diabetes," said Dr Victoria King, Research Manager at Diabetes UK. "We know that approximately 100 people a week in the UK lose a toe, foot or lower limb due to diabetes. "Managing blood glucose levels by keeping them within acceptable limits can cut the risk of diabetes-related amputations, and trials like this one guide us towards further ways of reducing the risk of diabetes associated amputations." Diabetes UK


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009